Search

Your search keyword '"Fonsart, Julien"' showing total 27 results
Start Over Author "Fonsart, Julien"
27 results on '"Fonsart, Julien"'

1. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

Author

Aboulker, Jean-Pierre, Bajos, Nathalie, Baril, Jean-Guy, Besnier, Michel, Binesse, Johan, Carette, Diane, Cattin, Grégoire, Chéret, Antoine, Chidiac, Christian, Choucair, Elias, Delfraissy, Jean-François, Demoulin, Baptiste, Diallo, Alpha, Durant-Zaleski, Isabelle, Doré, Véronique, Etien, Nicolas, Euphrasie, Françoise, Fonsart, Julien, Foubert, Valérie, Gibowski, Séverine, Girard, Gabriel, Guillon, Brigitte, Le Mestre, Soizic, Lert, France, Leturque, Nicolas, Lorente, Nicolas, Mennecier, Anaïs, Morin, Michel, Netzer, Emmanuelle, Otis, Joanne, Pasquet, Armelle, Peytavin, Gilles, Pialoux, Gilles, Préau, Marie, Rabian, Cécile, Rozenbaum, Willy, Sagaon-Teyssier, Luis, Saïdi, Yacine, Saouzanet, Marine, Simon, Marie-Christine, Suzan-Monti, Marie, Thompson, David, Timsit, Julie, Trottier, Benoît, Wainberg, Mark, Antoni, Guillemette, Tremblay, Cécile, Delaugerre, Constance, Charreau, Isabelle, Cua, Eric, Rojas Castro, Daniela, Raffi, François, Chas, Julie, Huleux, Thomas, Spire, Bruno, Capitant, Catherine, Cotte, Laurent, Meyer, Laurence, and Molina, Jean-Michel

Published
2020
Full Text
View/download PDF

2. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial

Author

Pintado, C., Loze, B., Gatey, C., Ponscarme, D., Penot, P., Veron, R., Delgado, J., Dalle, E., Parlier, S., Madelaine, I., Danet, M., Mahjoub, N., Mezreb, N., Moudachirou, K., Morel, S., Conort, G., Lorho, F., Meunier, M., Rozenbaum, W., Monfort, C., Foucoin, J., Boissavy, B., Cousseau, S., Huon, S., Djessima, A., Berrebi, V., Adda, A., le Nagat, S., Zarka, L., Berdougo, J., Mzoughi, N., Clement, F., Decouty, A., Chapolard, C., Godinot, M., Adouard-groslafeige, C., Koffi, J., Pansu, A., Becker, A., Pailhes, S., Bonnet, F., Jeanblanc, F., Brochier, C., Teruin, X., Rouby, S., Gilly, L., Etienne, C., Tolonin, F., Breaud, S., Péchenot, V., Bagge, S., Cepitelli, T., Roger, PM., Rosenthal, E., Cheret, A., Cornavin, P., Vandamme, S., Lambec, J., Dumon, N., Leclanche, O., Huleux, T., Biekre, R., Melliez, H., Bazus, H., Pasquet, A., Bernaud, C., Besnier, M., Bonnet, B., Hall, N., Cavellec, M., Hue, H., Larmet, L., Colas, M., Choquet, R., Fouéré, S, Netzer, E., Leturque, N., Binesse, J., Foubert, V., Saouzanet, M., Euphrasie, F., Guillon, B., Saïdi, Y., Suzan, M., Cattin, G., Demoulin, B., Lorente, N., Molina, Jean-Michel, Charreau, Isabelle, Chidiac, Christian, Pialoux, Gilles, Cua, Eric, Delaugerre, Constance, Capitant, Catherine, Rojas-Castro, Daniela, Fonsart, Julien, Bercot, Béatrice, Bébéar, Cécile, Cotte, Laurent, Robineau, Olivier, Raffi, François, Charbonneau, Pierre, Aslan, Alexandre, Chas, Julie, Niedbalski, Laurence, Spire, Bruno, Sagaon-Teyssier, Luis, Carette, Diane, Mestre, Soizic Le, Doré, Veronique, and Meyer, Laurence

Published
2018
Full Text
View/download PDF

3. Sexual health needs of female sex workers in Côte d’Ivoire: a mixed-methods study to prepare the future implementation of pre-exposure prophylaxis (PrEP) for HIV prevention

Author

Camille Anoma, Valentine Becquet, Marcellin Nouaman, Mélanie Plazy, Jean-Marie Masumbuko, Soh Kouame, Christine Danel, Serge Paul Eholie, Joseph Larmarange, Aboubakar Sangaré, Anglaret Xavier, Anoma Camille, Barin Francis, Bazin Brigitte, Becquet Valentine, Dabis François, Danel Christine, Eholie Serge, Ekouevi Didier, Fonsart Julien, Gbosi Kate, Kwamé Abo, Larmarange Joseph, Masumbuko Jean-Marie, Moh Raoul Méda Nicolas, Molina Jean-Michel, N’dri-Yoman Thérèse, Nouaman Marcellin, Plazy Mélanie, Tanoe Solange, and Yeo Roselyne

Subjects
Medicine
Abstract

Objective To describe sexual and reproductive health (SRH) needs of female sex workers (FSWs) to inform the future implementation of pre-exposure prophylaxis (PrEP) for HIV prevention in this population.Design and setting The ANRS 12361 PrEP-CI cross-sectional and mixed-methods study was designed and implemented with two community-based organisations in Côte d’Ivoire.Participants A convenience sample of 1000 FSWs aged ≥18, not known as HIV-positive, completed a standardised questionnaire assessing sociodemographic characteristics, sexual practices, use of community health services and a priori acceptability of PrEP. Twenty-two indepth interviews and eight focus group discussions were also conducted to document FSWs’ risky practices and sexual behaviours, experiences with violence and discrimination, attitudes regarding HIV and sexually transmitted infections (STIs), and barriers to SRH services.Results Although 87% described consistent condom use with clients, more than 22% declared accepting condomless sexual intercourse for a large sum of money. Furthermore, condom use with their steady partner and knowledge of their partner’s HIV status were low despite their acknowledged concurrent sexual partnerships. While inconsistent condom use exposed FSWs to STIs and undesired pregnancies, the prevalence of contraceptive strategies other than condoms was low (39%) due to fear of contraception causing sterility. FSWs faced obstacles to accessing SRH care and preferred advice from their peers or self-medication.Conclusions Despite adoption of preventive behaviour in most cases, FSWs are still highly exposed to HIV. Furthermore, FSWs seem to face several barriers to accessing SRH. Implementing PrEP among FSWs in West Africa, such as in Côte d’Ivoire, constitutes an opportunity to consider the regular follow-up of HIV-negative FSWs. PrEP initiation should not condition access to SRH services; conversely, SRH services could be a way to attract FSWs into HIV prevention. Our results highlight the importance of developing a people-focused approach that integrates all SRH needs when transitioning from PrEP efficacy trials to implementation.

Published
2020
Full Text
View/download PDF

4. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

Author

Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P, Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon-Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C, Diallo, A, Gibowski, S, Delfraissy, J F, Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Molina, Jean-Michel, Wainberg, Mark A, Trottier, Benoit, Tremblay, Cécile, Baril, Jean-Guy, Pialoux, Gilles, Cotte, Laurent, Chéret, Antoine, Pasquet, Armelle, Cua, Eric, Besnier, Michel, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand-Zaleski, Isabelle, Meyer, Laurence, Aboulker, Jean-Pierre, Spire, Bruno, Suzan-Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Capitant, Catherine, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie-Christine, Charreau, Isabelle, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, Rabian, Cecile, Chas, Julie, Tremblay, Cecile, Rojas-Castro, Daniela, Bernaud, Camille, Pintado, Claire, Sagaon-Teyssier, Luis, Mestre, Soizic Le, Ponscarme, Diane, and Doré, Veronique

Published
2017
Full Text
View/download PDF

5. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis

Author

Liegeon, Geoffroy, Antoni, Guillemette, Pialoux, Gilles, Capitant, Catherine, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cécile, Cua, Eric, Senneville, Eric, Raffi, François, Meyer, Laurence, Molina, Jean?Michel, Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P., Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon?Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C., Diallo, A, Gibowski, S, Delfraissy, J F., Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Wainberg, Mark A., Trottier, Benoit, Baril, Jean?Guy, Chéret, Antoine, Pasquet, Armelle, Hall, Nolwenn, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand?Zaleski, Isabelle, Aboulker, Jean?Pierre, Spire, Bruno, Suzan?Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie?Christine, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, and Rabian, Cecile

Subjects
MSM (Men who have sex with men) -- Health aspects, Tenofovir -- Patient outcomes, Glomerular filtration rate -- Testing, Emtricitabine -- Patient outcomes, HIV infection -- Prevention, Health
Abstract

: Introduction: Daily pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on‐demand PrEP with TDF/FTC in HIV‐1 uninfected men. Methods: We used data from the randomized double‐blind placebo‐controlled ANRS‐IPERGAY trial and its open‐label extension conducted between February 2012 and June 2016 among HIV‐uninfected MSM starting on‐demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study. Results: During the blind phase, with a median follow‐up of 9.4 months, the mean decline slope of eGFR from baseline was −0.88 and −1.53 mL/min/1.73 m[sup.2] per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m[sup.2] per year (p = 0.27). Including both phases, 389 participants started on‐demand TDF/FTC with a median follow‐up of 19.2 months and a mean decline of eGFR from baseline of −1.14 mL/min/1.73 m[sup.2] per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR ≤ 90 mL/min/1.73 m[sup.2] (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose‐response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of −0.88 mL/min/1.73 m[sup.2] between >15 pills/month vs. ≤15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to ≤2 ng/mL: >2 to ≤10ng/mL: −0.98 mL/min/1.73 m[sup.2], >10 to ≤40ng/mL: −1.28 mL/min/1.73 m[sup.2], >40 ng/mL: −1.82 mL/min/1.73 m[sup.2], p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m[sup.2] during the OLE phase. No case of Fanconi syndrome was reported. Conclusions: The renal safety of on‐demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety., Introduction Pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) – emtricitabine (FTC) raises a lot of expectations to hamper HIV epidemic due to its high effectiveness to prevent HIV acquisition [...]

Published
2020
Full Text
View/download PDF

7. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

Author

Fonsart, Julien, Saragosti, Sentob, Taouk, Milad, Peytavin, Gilles, Bushman, Lane, Charreau, Isabelle, Hance, Allan, Goldwirt, Lauriane, Morel, Stéphane, Mammano, Fabrizio, Loze, Bénédicte, Capitant, Catherine, Clavel, François, Mahjoub, Nadia, Meyer, Laurence, Anderson, Peter L., Delaugerre, Constance, and Molina, Jean-Michel

Published
2017
Full Text
View/download PDF

8. Ascorbic Acid Deficiency Prevalence and Associated Cognitive Impairment in Alcohol Detoxification Inpatients: A Pilot Study

Author

Clergue-Duval, Virgile, primary, Azuar, Julien, additional, Fonsart, Julien, additional, Delage, Clément, additional, Rollet, Dorian, additional, Amami, Jihed, additional, Frapsauce, Alexia, additional, Gautron, Marie-Astrid, additional, Hispard, Eric, additional, Bellivier, Frank, additional, Bloch, Vanessa, additional, Laplanche, Jean-Louis, additional, Questel, Frank, additional, and Vorspan, Florence, additional

Published
2021
Full Text
View/download PDF

9. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

Author

Molina, Jean-Michel, Capitant, Catherine, Spire, Bruno, Pialoux, Gilles, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cecile, Le Gall, Jean-Marie, Cua, Eric, Pasquet, Armelle, Raffi, François, Pintado, Claire, Chidiac, Christian, Chas, Julie, Charbonneau, Pierre, Delaugerre, Constance, Suzan-Monti, Marie, Loze, Benedicte, Fonsart, Julien, Peytavin, Gilles, Cheret, Antoine, Timsit, Julie, Girard, Gabriel, Lorente, Nicolas, Préau, Marie, Rooney, James F., Wainberg, Mark A., Thompson, David, Rozenbaum, Willy, Doré, Veronique, Marchand, Lucie, Simon, Marie-Christine, Etien, Nicolas, Aboulker, Jean-Pierre, Meyer, Laurence, and Delfraissy, Jean-François

Published
2015
Full Text
View/download PDF

13. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

Author

Antoni, Guillemette, primary, Tremblay, Cécile, additional, Delaugerre, Constance, additional, Charreau, Isabelle, additional, Cua, Eric, additional, Rojas Castro, Daniela, additional, Raffi, François, additional, Chas, Julie, additional, Huleux, Thomas, additional, Spire, Bruno, additional, Capitant, Catherine, additional, Cotte, Laurent, additional, Meyer, Laurence, additional, Molina, Jean-Michel, additional, Aboulker, Jean-Pierre, additional, Bajos, Nathalie, additional, Baril, Jean-Guy, additional, Besnier, Michel, additional, Binesse, Johan, additional, Carette, Diane, additional, Cattin, Grégoire, additional, Chéret, Antoine, additional, Chidiac, Christian, additional, Choucair, Elias, additional, Delfraissy, Jean-François, additional, Demoulin, Baptiste, additional, Diallo, Alpha, additional, Durant-Zaleski, Isabelle, additional, Doré, Véronique, additional, Etien, Nicolas, additional, Euphrasie, Françoise, additional, Fonsart, Julien, additional, Foubert, Valérie, additional, Gibowski, Séverine, additional, Girard, Gabriel, additional, Guillon, Brigitte, additional, Le Mestre, Soizic, additional, Lert, France, additional, Leturque, Nicolas, additional, Lorente, Nicolas, additional, Mennecier, Anaïs, additional, Morin, Michel, additional, Netzer, Emmanuelle, additional, Otis, Joanne, additional, Pasquet, Armelle, additional, Peytavin, Gilles, additional, Pialoux, Gilles, additional, Préau, Marie, additional, Rabian, Cécile, additional, Rozenbaum, Willy, additional, Sagaon-Teyssier, Luis, additional, Saïdi, Yacine, additional, Saouzanet, Marine, additional, Simon, Marie-Christine, additional, Suzan-Monti, Marie, additional, Thompson, David, additional, Timsit, Julie, additional, Trottier, Benoît, additional, and Wainberg, Mark, additional

Published
2020
Full Text
View/download PDF

15. Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial

Author

Gallien, Sébastien, Charreau, Isabelle, Fonsart, Julien, Mourah, Samia, Kalidi, Issa, Delobel, Pierre, Marchou, Bruno, Aboulker, Jean?Pierre, and Molina, Jean?Michel

Subjects
Antiviral agents -- Patient outcomes, Immunity -- Identification and classification -- Health aspects, AIDS (Disease) -- Research, AIDS research, HIV infection -- Development and progression -- Drug therapy, Health
Abstract

Introduction: In the SMART trial, baseline plasma hsCRP, IL6 and D‐dimer levels were strongly correlated to all‐cause mortality. A case‐control study has shown an increase of IL‐6 and D‐dimer levels after one month of antiretroviral therapy (ART) interruption, which was correlated to viral load. Restarting ART was associated to a decrease in D‐dimer but not IL‐6 or hsCRP levels. We assessed biomarkers levels up to 96 weeks in ART‐experienced adults with plasma HIV RNA levels Methods: Stored plasma for 160 participants (80 IT and 80 CT), matched by age, sex and CDC classification, were analyzed blinded for IL‐6, sCD‐14, hsCRP and D‐dimer levels at baseline, week 8 (IT group only), week 16 and week 96. Lower levels of detection for IL‐6, sCD14, hsCRP and D‐Dimer were 1.5 pg/mL, 250 ng/mL, 0.03 µg/mL and 0.21 µg/mL, respectively. The primary objective was to compare changes in IL‐6, hsCRP, sCD14 and D‐dimer plasma levels from baseline to week 8, 16 and 96 in the IT and CT arms. Biomarkers levels were log10 transformed prior to analysis. Results: At baseline, patients were mostly men (86%), with a median age of 40 years, a CD4+ T‐cell count of 768/mm[sup.3], have received a median of 4.7 years of ART and 85% had HIV RNA Compared to baseline, D‐dimer levels significantly increased 8 weeks after ART interruption in the IT arm (+23% fold change, 95% CI +9% to +39%) but reverted to baseline levels at week 16 and remained unchanged at week 96. There was no significant change from baseline in the other biomarker levels in the IT arm. Similarly, no significant change from baseline in biomarker levels was seen in the CT arm up to 96 weeks. Conclusion: Coagulation and inflammatory biomarkers levels remained stable over 96 weeks in well‐suppressed HIV‐infected patient on ART. Following ART interruption there was a significant increase in D‐dimer but not in inflammatory biomarkers levels. This increase was reversed upon reintroduction of ART. These data suggest that ART interruption increases coagulation rather than inflammatory biomarkers., Table 1: Changes in biomarkers levels in participants from the intermittent (IT) vs continuous (CT) treatment arms through 96 weeks (*p=0.002, Wilcoxon test) IL‐6(pg/mL) sCD14(ng/mL) hsCRP(#x00B5;g/mL) D‐dimer(µg/mL) IT CT IT [...]

Published
2014
Full Text
View/download PDF

16. Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial.

Author

Bauer, Rebecca, Netzer, Emmanuelle, Pintado, Claire, Capitant, Catherine, Cua, Eric, Etien, Nicolas, Fonsart, Julien, Pialoux, Gilles, Chidiac, Christian, Etienne, Cédric, Doré, Véronique, Meyer, Laurence, and Molina, Jean-Michel

Subjects
CLINICAL drug trials, HIV prevention, CONDOMS, PREVENTIVE medicine, PATIENT compliance, QUESTIONNAIRES, SELF-evaluation, ANAL sex, MEN who have sex with men, EMTRICITABINE-tenofovir, DESCRIPTIVE statistics
Abstract

We assessed the coverage of sex acts by event-driven pre-exposure prophylaxis (ED-PrEP) over a 2-month period in 54 participants in the open label phase of the ANRS Ipergay trial. Participants received an electronic monitoring system device to record bottle openings. Self-questionnaires collected daily information on PrEP intake and sexual behavior. Intake was also estimated through returned pill counts. Full coverage of sex acts was defined as at least one pill taken both within 24 h before and within 48 h following sex. There was a strong correlation (r = − 0.92) between the number of bottle openings and returned pill counts. During the study, 42 participants (78%) practiced ED-PrEP and 12 (22%) daily PrEP with bottle openings at least 5 days/week whatever their sexual activity. Out of the 154 reported receptive anal sex acts, 81% were condomless: among them, PrEP coverage was hight: 97% among those practicing daily PrEP and 82% among those using ED-PrEP. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial

Author

Molina, Jean-Michel, primary, Charreau, Isabelle, additional, Chidiac, Christian, additional, Pialoux, Gilles, additional, Cua, Eric, additional, Delaugerre, Constance, additional, Capitant, Catherine, additional, Rojas-Castro, Daniela, additional, Fonsart, Julien, additional, Bercot, Béatrice, additional, Bébéar, Cécile, additional, Cotte, Laurent, additional, Robineau, Olivier, additional, Raffi, François, additional, Charbonneau, Pierre, additional, Aslan, Alexandre, additional, Chas, Julie, additional, Niedbalski, Laurence, additional, Spire, Bruno, additional, Sagaon-Teyssier, Luis, additional, Carette, Diane, additional, Mestre, Soizic Le, additional, Doré, Veronique, additional, Meyer, Laurence, additional, Pintado, C., additional, Loze, B., additional, Gatey, C., additional, Ponscarme, D., additional, Penot, P., additional, Veron, R., additional, Delgado, J., additional, Dalle, E., additional, Parlier, S., additional, Madelaine, I., additional, Danet, M., additional, Mahjoub, N., additional, Mezreb, N., additional, Moudachirou, K., additional, Morel, S., additional, Conort, G., additional, Lorho, F., additional, Meunier, M., additional, Rozenbaum, W., additional, Monfort, C., additional, Foucoin, J., additional, Boissavy, B., additional, Cousseau, S., additional, Huon, S., additional, Djessima, A., additional, Berrebi, V., additional, Adda, A., additional, le Nagat, S., additional, Zarka, L., additional, Berdougo, J., additional, Mzoughi, N., additional, Clement, F., additional, Decouty, A., additional, Chapolard, C., additional, Godinot, M., additional, Adouard-groslafeige, C., additional, Koffi, J., additional, Pansu, A., additional, Becker, A., additional, Pailhes, S., additional, Bonnet, F., additional, Jeanblanc, F., additional, Brochier, C., additional, Teruin, X., additional, Rouby, S., additional, Gilly, L., additional, Etienne, C., additional, Tolonin, F., additional, Breaud, S., additional, Péchenot, V., additional, Bagge, S., additional, Cepitelli, T., additional, Roger, PM., additional, Rosenthal, E., additional, Cheret, A., additional, Cornavin, P., additional, Vandamme, S., additional, Lambec, J., additional, Dumon, N., additional, Leclanche, O., additional, Huleux, T., additional, Biekre, R., additional, Melliez, H., additional, Bazus, H., additional, Pasquet, A., additional, Bernaud, C., additional, Besnier, M., additional, Bonnet, B., additional, Hall, N., additional, Cavellec, M., additional, Hue, H., additional, Larmet, L., additional, Colas, M., additional, Choquet, R., additional, Fouéré, S, additional, Netzer, E., additional, Leturque, N., additional, Binesse, J., additional, Foubert, V., additional, Saouzanet, M., additional, Euphrasie, F., additional, Guillon, B., additional, Saïdi, Y., additional, Suzan, M., additional, Cattin, G., additional, Demoulin, B., additional, and Lorente, N., additional

Published
2018
Full Text
View/download PDF

18. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

Author

Molina, Jean-Michel, primary, Charreau, Isabelle, additional, Spire, Bruno, additional, Cotte, Laurent, additional, Chas, Julie, additional, Capitant, Catherine, additional, Tremblay, Cecile, additional, Rojas-Castro, Daniela, additional, Cua, Eric, additional, Pasquet, Armelle, additional, Bernaud, Camille, additional, Pintado, Claire, additional, Delaugerre, Constance, additional, Sagaon-Teyssier, Luis, additional, Mestre, Soizic Le, additional, Chidiac, Christian, additional, Pialoux, Gilles, additional, Ponscarme, Diane, additional, Fonsart, Julien, additional, Thompson, David, additional, Wainberg, Mark A, additional, Doré, Veronique, additional, Meyer, Laurence, additional, Meyer, L, additional, Capitant, C, additional, Charreau, I, additional, Netzer, E, additional, Leturque, N, additional, Binesse, J, additional, Foubert, V, additional, Saouzanet, M, additional, Euphrasie, F, additional, Carette, D, additional, Guillon, B, additional, Saïdi, Y, additional, Aboulker, J P, additional, Spire, B, additional, Suzan, M, additional, Cattin, G, additional, Demoulin, B, additional, Sagaon-Teyssier, L, additional, Lorente, N, additional, Doré, V, additional, Choucair, E, additional, Le Mestre, S, additional, Mennecier, A, additional, Etien, N, additional, Simon, M C, additional, Diallo, A, additional, Gibowski, S, additional, Delfraissy, J F, additional, Thompson, D, additional, Sas, J, additional, Pankovitch, J, additional, Klein, M, additional, Anis, A, additional, Molina, Jean-Michel, additional, Trottier, Benoit, additional, Tremblay, Cécile, additional, Baril, Jean-Guy, additional, Chéret, Antoine, additional, Besnier, Michel, additional, Rozenbaum, Willy, additional, Bajos, Nathalie, additional, Timsit, Julie, additional, Peytavin, Gilles, additional, Durand-Zaleski, Isabelle, additional, Aboulker, Jean-Pierre, additional, Suzan-Monti, Marie, additional, Girard, Gabriel, additional, Castro, Daniela Rojas, additional, Préau, Marie, additional, Morin, Michel, additional, Mennecier, Anaïs, additional, Choucair, Elias, additional, Doré, Véronique, additional, Simon, Marie-Christine, additional, Otis, Joanne, additional, Lert, France, additional, Diallo, Alpha, additional, Gibowski, Séverine, additional, and Rabian, Cecile, additional

Published
2017
Full Text
View/download PDF

19. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

Author

Fonsart, Julien, primary, Saragosti, Sentob, additional, Taouk, Milad, additional, Peytavin, Gilles, additional, Bushman, Lane, additional, Charreau, Isabelle, additional, Hance, Allan, additional, Goldwirt, Lauriane, additional, Morel, Stéphane, additional, Mammano, Fabrizio, additional, Loze, Bénédicte, additional, Capitant, Catherine, additional, Clavel, François, additional, Mahjoub, Nadia, additional, Meyer, Laurence, additional, Anderson, Peter L., additional, Delaugerre, Constance, additional, and Molina, Jean-Michel, additional

Published
2016
Full Text
View/download PDF

20. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study

Author

Gazaignes, Sandrine, primary, Resche-Rigon, Matthieu, additional, Gatey, Caroline, additional, Yang, Chloe, additional, Denis, Blandine, additional, Fonsart, Julien, additional, Desseaux, Kristell, additional, Guionie, Michel, additional, Rozenbaum, Willy, additional, Delaugerre, Constance, additional, and Molina, Jean-Michel, additional

Published
2015
Full Text
View/download PDF

27. Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study

Author

Gazaignes, Sandrine, Resche-Rigon, Matthieu, Gatey, Caroline, Yang, Chloe, Denis, Blandine, Fonsart, Julien, Desseaux, Kristell, Guionie, Michel, Rozenbaum, Willy, Delaugerre, Constance, and Molina, Jean-Michel

Abstract

Background Rilpivirine (RPV) is a second-generation once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non-inferior antiviral activity to efavirenz in treatment-naive patients. Data in treatment-experienced patients are more limited. We wished to assess the efficacy and safety of a switch to RPV-based regimens in well-suppressed treatment-experienced patients.Methods Between September 2012 and June 2013, all antiretroviral therapy (ART)-experienced HIV-1-infected patients with a plasma HIV RNA level <50 copies/ml, and switching to an RPV-based regimen, were analysed in this retrospective observational monocentric cohort study. The primary end point was the proportion of patients with virological success defined as a plasma HIV RNA level <50 copies/ml at 12 months using the FDA snapshot algorithm.Results A total of 281 participants were studied and 97% received a combination of RPV/tenofovir disoproxil fumarate/emtricitabine. At month 12, the rate of virological success was 59% and increased to 72% using available data beyond month 12. Sixteen (6%) patients experienced virological failure, which was associated with the presence of the M184V/I resistance mutation in prior genotypes (P=0.02) and the use of a non-NNRTI as third agent before the switch (P=0.03). RPV-based regimens were overall well tolerated and only 23 (8%) patients discontinued ART because of adverse events, mostly neuropsychiatric adverse events. Switching to RPV was associated with significant but modest improvement of the lipid profile.Conclusions In patients fully suppressed on ART, a switch to an RPV-based regimen should only be considered in the absence of prior virological failure or resistance mutations to nucleoside reverse transcriptase inhibitors and NNRTIs to avoid virological failures.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results